Medtronic acquires chitosan-dextran gel technology, which the company hopes will one day make endoscopic sinus treatments safer.
The world’s largest medical device maker bought the rights to a technology that it hopes can one day develop products for functional endoscopic sinus surgery.
Minneapolis-based Medtronic Inc. (NYSE:MDT) said that the so-called chitosan-dextran gel technology was acquired from Robinson Squidgel Ltd., the University of Adelaide in Australia and the University of Otago in New Zealand.
A Medtronic spokesman declined to provide the purchase price for the technology.
InspireMD presents new 6 month follow-up data showing better survival rates for its MGuard stent
Symbios Medical Products recalls 2 years' worth of its GoPump systems and GOBlock kits after...
Covidien's MicroStream MicroPod respiratory monitoring module hits the shelves
The newly unveiled iteration of the Microsoft Xbox One's Kinect camera demonstrates the ability to...
If you read nothing else today, make sure you're still in the know with MassDevice +3.